CG Oncology (CGON) Accumulated Depreciation (2024 - 2026)

CG Oncology's (CGON) quarterly Accumulated Depreciation came in at $2.3 million in Q1 2026, up 55.63% on a QoQ basis from $1.5 million in Q4 2025.

CG Oncology (CGON) Accumulated Depreciation (2024 - 2026) Analysis & Trends

CG Oncology (CGON) has 3 years of Accumulated Depreciation data on file, last reported at $2.3 million in Q1 2026.

Quarterly Accumulated Depreciation changed N/A year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, up 1594.25% from the prior year.
Accumulated Depreciation advanced to $2.3 million in Q1 2026, from $1.5 million in the prior quarter.
In the past five years, Accumulated Depreciation ranged from a high of $2.3 million in Q1 2026 to a low of $87000.0 in Q4 2024.
A 3-year average of $1.1 million and a median of $1.0 million in 2025 frame the typical range for Accumulated Depreciation.
The widest YoY moves for Accumulated Depreciation: up 1594.25% in 2025, down 1594.25% in 2025.
Tracing CGON's Accumulated Depreciation over 3 years: stood at $87000.0 in 2024, then soared by 1594.25% to $1.5 million in 2025, then jumped by 55.63% to $2.3 million in 2026.
The last three Accumulated Depreciation figures came in at $2.3 million (Q1 2026), $1.5 million (Q4 2025), and $623000.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CG Oncology	6.63 Bn	6.63 Bn	-2.77 Mn

Download Data